AMGN241227P285000
- 21.80
- 0.000.00%
Amgen Newsroom
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Santa Claus Came Without Rallying the Troops | Live Stock
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.
CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides
Piper Sandler Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $310
Amgen Is Maintained at Overweight by Piper Sandler
Analyst Expectations For Amgen's Future
Amgen Analyst Ratings
Express News | Amgen Inc : Piper Sandler Cuts Target Price to $310 From $344
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
Express News | UK's Mhra: Tarlatamab Approved to Treat Adult Patients With Small Cell Lung Cancer
These Are the Best and Worst Stocks This Year -- Barrons.com
This Biotech Is One of the S&P 500's Worst Performers. It Looks Too Cheap. -- Barrons.com
Is Amgen Inc. (AMGN) the Best Pharma Dividend Stock to Buy In 2024?
Dow's Nearly 225-Point Drop Led By Losses In Nike, Boeing Stocks
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Weekly Buzz: So far, Santa is Letting us Down
Looking At Amgen's Recent Unusual Options Activity